Enoblituzumab, previously known as TJ-271 or MGA271, represents a unique therapeutic directed at CD33, the marker found predominantly on blood tissues. The antibody operates as the dual-action therapy, concurrently https://zakariacvps166737.pointblog.net/enoblituzumab-a-deep-dive-into-tj-271-and-mga271-93171364